Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 40,000 shares at $30.33 ($1.2M) on 2022-11-02, disclosed to the SEC on 2022-11-03.
Open-market sale of $1.2M DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.20 | 8,748 | $264K | 21.8% |
| 2 | $30.20 | 8,748 | $264K | 21.8% |
| 3 | $30.33 | 11,252 | $341K | 28.2% |
| 4 | $30.33 | 11,252 | $341K | 28.2% |
| Total | $30.27 avg | 40,000 | $1.2M | 100% |
| Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |
| DNLI | SELL | 2022-07-27 | $712K | — | Filing → |